SCHEMBL10063111

SCHEMBL10063111

CCc1ccc(NC(=O)c2cc(-c3ccncc3)c[nH]c2=O)cc1

nearest known ligand 0.70

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALK Q9UM73 7/20 0.70
▸ ITK Q08881 8/20 0.65
▸ INSR P06213 6/20 0.52
▸ RAB9A P51151 2/20 0.51
▸ CFTR P13569 1/20 0.51
▸ TTK P33981 2/20 0.48
▸ AURKB Q96GD4 2/20 0.48
▸ INCENP Q9NQS7 2/20 0.48
▸ NPC1 O15118 1/20 0.48
▸ AURKA O14965 1/20 0.47
▸ ABL1 P00519 2/20 0.47
▸ NPM1 P06748 2/20 0.47
▸ BCR P11274 2/20 0.47
▸ GPR142 Q7Z601 1/20 0.47
▸ FLT3 P36888 3/20 0.47
▸ KIT P10721 2/20 0.47
▸ SRC P12931 2/20 0.47
▸ IGF1R P08069 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10063192 0.88 ALK (0.58) ALKITKRAB9ATTKAURKB
SCHEMBL10063187 0.85 ALK (0.61) ALKITKINSRRAB9ATTK
SCHEMBL10063116 0.84 ITK (0.67) ALKITKINSRRAB9ATTK
SCHEMBL15850171 0.84 ITK (0.67) ALKITKCFTRTTKAURKB
SCHEMBL10063126 0.84 ITK (0.67) ALKITKINSRCFTRTTK
SCHEMBL10063128 0.84 ITK (0.64) ALKITKINSRRAB9ACFTR
SCHEMBL10063120 0.84 ITK (0.64) ALKITKINSRRAB9ATTK
SCHEMBL10063177 0.81 ITK (0.62) ALKITKTTKAURKBINCENP
SCHEMBL10063189 0.80 ITK (0.77) ALKITKINSRRAB9ATTK
SCHEMBL10063117 0.80 ITK (0.61) ALKITKRAB9ATTKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1831168-B1 PYRID-2-ONES USEFUL AS INHIBITORS OF TEC FAMILY PROTEIN KINASES FOR THE TREATMENT OF INFLAMMATORY, PROLIFERATIVE AND IMMUNOLOGICALLY-MEDIATED DISEASES. VERTEX PHARMA (US) 2014-07-02 — — EP disclosed
US-20130184259-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-18 — — US disclosed
US-20130184259-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-07-18 — — US disclosed
US-8338597-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-25 — — US disclosed
US-8338597-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-12-25 — — US disclosed
US-20120190699-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-26 — — US disclosed
US-20120190699-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-26 — — US disclosed
US-8101770-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-24 — — US disclosed
US-8101770-B2 Pyridones useful as inhibitors of kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190699-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES MAP3K20, MAP3K6, MAP3K5 ALK 581/4885ITK 393/4885INSR 2559/4885
US-20130184259-A1 PYRIDONES USEFUL AS INHIBITORS OF KINASES MAP3K20, MAP3K6, MAP3K5 ALK 581/4885ITK 393/4885INSR 2559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback